AI-powered biotechnology company ExpressionEdits has raised USD 13 million in a seed funding round led by Octopus Ventures and redalpine, with contributions from BlueYard Capital and Wilbe Capital, among others.
The proceeds will be directed toward accelerating candidate selection for the company’s ongoing preclinical studies and developing its pipeline of protein-based therapeutics, with a focus on recombinant proteins faced with manufacturing challenges based on current technology.
ExpressionEdits is a cutting-edge company that optimizes gene design through its unique intronization technology. This approach manipulates the genetic structure by integrating multiple short noncoding DNA sections, advancing gene expression and leading to improved protein production.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.